Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00751062 |
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
Condition | Intervention | Phase |
---|---|---|
Open Angle Glaucoma Ocular Hypertension |
Drug: timolol Drug: PhXA41 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in Scandinavia |
Enrollment: | 267 |
Study Start Date: | November 1992 |
Study Completion Date: | December 1993 |
Primary Completion Date: | December 1993 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Timolol: Active Comparator |
Drug: timolol
One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
|
PhXA41: Experimental |
Drug: PhXA41
One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
|
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |
Pfizer Investigational Site | |
Hellerup, Denmark | |
Pfizer Investigational Site | |
Vejle, Denmark | |
Finland | |
Pfizer Investigational Site | |
Oulu, Finland | |
Norway | |
Pfizer Investigational Site | |
Trondheim, Norway | |
Pfizer Investigational Site | |
Oslo, Norway | |
Pfizer Investigational Site | |
Bergen, Norway | |
Sweden | |
Pfizer Investigational Site | |
Uppsala, Sweden | |
Pfizer Investigational Site | |
Huddinge, Sweden, 141 86 | |
Pfizer Investigational Site | |
Linkoping, Sweden, 581 85 | |
Pfizer Investigational Site | |
Lund, Sweden | |
Pfizer Investigational Site | |
Malmo, Sweden, 205 02 | |
Pfizer Investigational Site | |
Umea, Sweden | |
Pfizer Investigational Site | |
Gothenburg, Sweden |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | 9200PG006, A6111130 |
Study First Received: | September 10, 2008 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00751062 |
Health Authority: | United States: Food and Drug Administration |
open angle glaucoma
ocular hypertension |
Glaucoma Eye Diseases Glaucoma, Open-Angle Vascular Diseases |
Timolol Latanoprost Hypertension Ocular Hypertension |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses Physiological Effects of Drugs Adrenergic beta-Antagonists |
Adrenergic Antagonists Cardiovascular Diseases Cardiovascular Agents Anti-Arrhythmia Agents Antihypertensive Agents Pharmacologic Actions |